SEngine Precision Medicine: SEngine Precision Medicine Announces New Collaboration to Bring PARIS Test to Patients with CNS Cancers
SEngine Precision Medicine and Dana-Farber Cancer Institute today announced a collaboration to bring SEngine's PARIS® Test to adult and pediatric patients with primary or metastatic solid-tumor central nervous system (CNS) cancers.
Read full article »
SEngine is a Washington-based biotechnology company that researches and develops precision medicine for the treatment of cancer.
Read more